The company is a partnership between the Malaghan Institute and tech incubator Bridgewest Ventures NZ, and is aimed at scaling up cancer immunotherapy trials in New Zealand through the use of compact cocoon-like machines. “It could be more in future, depending on what results of clinical trials are,” Malaghan clinical director Robert Weinkove ​said. BioOra will provide contract manufacturing services to the Institute for future CAR T-cell clinical trials. BioOra director John Robson, also New Zealand general manager of Bridgewest Ventures, said the automation of CAR T-cell therapy was a game-changer. KEVIN STENT/STUFF The Government announced an $14.4m investment into new science research, including the cutting edge CAR T-cell cancer treatment at the Malaghan Institute.

Source: Stuff September 22, 2021 23:02 UTC